In Brief: Novopharm ranitidine
This article was originally published in The Tan Sheet
Executive Summary
Novopharm ranitidine: Company will market its Form 1 generic version of the prescription H2 antagonist on July 10, 16 days prior to expiration of Glaxo Wellcome's patent protection for Zantac (Form 2 ranitidine), pursuant to a licensing agreement announced April 24. The Form 1 patent expires July 25. Novopharm will pay Glaxo licensing fees in return for the 16-day generic exclusivity. Glaxo agreed not to appeal its Form 1 patent cases against Novopharm to the Supreme Court after a federal appeals court affirmed April 6 a lower court decision that Novopharm should be allowed to market its Form 1 generic after July 25 ("The Tan Sheet" Jan. 13, p. 19)...